Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT ID: NCT01057095
Last Updated: 2015-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2010-01-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at gene expression in tissue samples from patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01520246
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01139333
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
NCT01500499
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia
NCT00897936
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia
NCT01139931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Screen acute myeloid leukemia (AML) samples to correlate high relative expression levels of PLAGL2 and putative PLAGL2 target genes (implicated in microarray study) with potential pathogenic relevance with respect to AML development.
OUTLINE: Cryopreserved mRNA from diagnostic samples is analyzed for gene expression by reverse transcriptase-PCR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
gene expression analysis
reverse transcriptase-polymerase chain reaction
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia, including inv(16)(p13;q22) abnormalities
* No t(15;17)(q22;q12) or t(8;21)(q22;q22) abnormalities
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Soheil Meshinchi, MD
Role: PRINCIPAL_INVESTIGATOR
Fred Hutchinson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML10B12
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000664240
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02208
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML10B12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.